{"nctId":"NCT01014689","briefTitle":"Comparison of Epiduo Associated With Lymecycline Versus Epiduo Vehicle Associated With Lymecycline in Acne Vulgaris","startDateStruct":{"date":"2009-08"},"conditions":["Acne Vulgaris"],"count":378,"armGroups":[{"label":"Adapalene 0.1% / BPO 2.5% gel","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Adapalene/ BPO gel with Lymecycline capsules"]},{"label":"Adapalene 0.1% / BPO 2.5% Vehicle Gel","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Adapalene/ BPO vehicle gel with Lymecycline capsules"]}],"interventions":[{"name":"Adapalene/ BPO gel with Lymecycline capsules","otherNames":["Adapalene/BPO with Lymecycline"]},{"name":"Adapalene/ BPO vehicle gel with Lymecycline capsules","otherNames":["Adapalene/BPO vehicle with Lymecycline"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female Subjects of any race, aged 12 to 35 years inclusive,\n2. Subjects with moderate to severe facial acne vulgaris (Investigator's Global Assessment score of 3 or 4),\n\nExclusion Criteria:\n\n1. Subjects with more than 3 nodules or cysts on the face\n2. Subjects with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.),\n3. Subjects with a wash-out period for topical treatment on the face less than: Corticosteroids, antibiotics, antibacterials, antiseptics, retinoids, other anti-inflammatory drugs or other acne treatments (2 weeks), Zinc containing drugs (1 week), Phototherapy devices for acne and cosmetic procedures (1 week)\n4. Subjects with a wash-out period for systemic treatment less than:Acne therapy containing zinc (4 weeks), Corticosteroids, antibiotics (4 weeks), Other acne treatments (6 months), Ciproterone acetate / Chlormadinone acetate (6 months), Spironolactone / Drospirenone (3 months)\n5. Subjects with impaired hepatic (ALT/AST \\> 3xULN and bilirubin \\> 1.5xULN) or renal (creatinine clearance greater than 60 ml/min) functions based on a blood sample,\n6. Subjects with known intolerance to lactose,","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"35 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Total Lesion Count","description":"Percent change from Baseline in Total Lesion count (sum of Non-Inflammatory and Inflammatory lesions) at Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-74.1","spread":null},{"groupId":"OG001","value":"-56.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Success Rate on the Investigator's Global Assessment (IGA) at Week 12","description":"Percentage of Subjects \"Clear\" or \"Almost Clear\" on 6-point IGA scale(0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe and 5=very severe) at Week 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.6","spread":null},{"groupId":"OG001","value":"33.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":191},"commonTop":["HEADACHE","NASOPHARYNGITIS"]}}}